# Chronic Myelogenous Leukemia

Chronic myelogenous leukemia requires molecularly confirmed BCR::ABL1 disease classification, early and serial standardized molecular monitoring, individualized tyrosine kinase inhibitor selection, and prompt evaluation of inadequate response, intolerance, adherence, interactions, and kinase-domain mutations to prevent progression.

**Clinical question:** How should physicians diagnose, monitor, and individualize tyrosine kinase inhibitor therapy for chronic-phase chronic myelogenous leukemia?

Updated: 2026-08-21T01:37:29.219695+00:00

## What matters in practice
- Establish CML with demonstration of the Philadelphia chromosome and/or BCR::ABL1 fusion; obtain marrow morphology and cytogenetics plus transcript characterization at baseline. [18][19]
- For chronic-phase CML, TKI therapy is the central disease-modifying treatment, with prevention of accelerated- or blast-phase progression as the primary therapeutic goal. [18]
- Use serial quantitative BCR::ABL1 testing standardized to the International Scale for response assessment; early molecular milestones guide reassessment rather than isolated test results alone. [21]
- An unsatisfactory response warrants assessment of adherence and drug interactions, with BCR::ABL1 kinase-domain mutation testing to inform a therapy change when clinically indicated. [3][21]
- TKI discontinuation with intensive molecular surveillance is feasible only in selected patients with sustained deep molecular response. [1][18]

## Confirm BCR::ABL1 disease and define baseline risk

Baseline testing should establish the molecular target, disease phase, and a reference point for longitudinal response assessment.

CML is defined by the Philadelphia chromosome, created by t(9;22), which produces a BCR::ABL1 fusion gene. Most patients in developed settings present in chronic phase, but phase assignment at diagnosis is essential because therapeutic goals and urgency differ substantially in accelerated- and blast-phase disease. [18]

Obtain complete blood count with differential, chemistry testing, physical examination including spleen assessment, bone marrow aspirate for morphology and conventional cytogenetics, and BCR::ABL1 testing. Baseline qualitative RT-PCR identifies the transcript type; quantitative RT-PCR provides the baseline molecular burden for later monitoring. Core biopsy is useful when aspiration is inadequate or marrow architecture requires assessment. [19]

Fluorescence in situ hybridization is principally useful when conventional cytogenetics does not demonstrate a Philadelphia chromosome but CML remains suspected. Baseline marrow cytogenetics also identifies additional chromosomal abnormalities that may affect disease assessment and subsequent interpretation of treatment response. [19]
- Document the BCR::ABL1 transcript type before treatment so the follow-up assay can reliably quantify the patient-specific transcript. [19]
- Obtain a baseline ECG and biochemical profile, including hepatitis B serology, as part of pretreatment assessment described in guideline-based diagnostic workups. [19]
- Do not rely on mutation testing at initial chronic-phase diagnosis: kinase-domain mutations are generally not detectable before TKI exposure with available methods. [3]

*Baseline studies used to establish and characterize CML. [18][19]*

| Study | Clinical purpose | Interpretive consequence |
| --- | --- | --- |
| Bone marrow aspirate with morphology and conventional cytogenetics | Determine disease phase and identify Philadelphia chromosome or additional cytogenetic abnormalities. [19] | Provides baseline morphologic and cytogenetic disease characterization. [19] |
| Qualitative RT-PCR for BCR::ABL1 | Confirm fusion transcript and identify transcript type. [19] | Enables selection and validation of the appropriate molecular monitoring assay. [19] |
| Quantitative RT-PCR for BCR::ABL1 | Establish molecular baseline and permit longitudinal response assessment. [19][21] | Follow serially using International Scale reporting when available. [21] |
| FISH | Evaluate suspected CML when marrow cytogenetics is Philadelphia chromosome-negative. [19] | Supports fusion detection in a discordant cytogenetic setting. [19] |

## Select frontline TKI therapy around disease-control and patient-specific goals

TKI therapy is standard for chronic-phase disease; selection is individualized rather than purely response-rate driven.

TKIs have transformed chronic-phase CML management and are highly effective at preventing progression to advanced disease. Current management increasingly balances durable disease control with tolerance, comorbidity burden, quality of life, and whether a patient may ultimately pursue treatment-free remission. [1][18]

Frontline chronic-phase treatment is based on TKI therapy in virtually all patients. Choice among agents should account for expected efficacy, prior cardiovascular and pulmonary history, metabolic risks, concomitant medications, toxicity tolerance, and patient preference; the available search evidence does not provide sufficient support for agent-specific U.S. dosing or a complete selection algorithm. [15][18]

Asciminib is a STAMP inhibitor that binds the ABL1 myristoyl pocket rather than the ATP-binding site targeted by conventional TKIs. It is described as an option for chronic-phase CML after resistance or intolerance to at least two TKIs, including T315I-positive disease; confirm current U.S. labeling, indication, and dose before prescribing because the supplied evidence is not an FDA label. [13]
- Review all concomitant drugs and adherence before designating a response as biologic TKI failure. [3][21]
- For patients expected to remain on lifelong therapy, optimize both molecular response and treatment-related quality of life. [1]
- Manage TKI adverse effects proactively; nilotinib has reported fluid retention, rash, pruritus, dry skin, and rare alopecia in published experience. [4]

### Pregnancy considerations

There is no established single standard of care for CML during pregnancy in the supplied literature. Interferon-based treatment is identified as a potential management option; decisions require coordinated hematology and maternal-fetal medicine input and individualized assessment of disease control versus fetal exposure. [17]

*Therapeutic decisions that should precede a TKI change. [3][21]*

| Clinical situation | Immediate assessment | Management implication |
| --- | --- | --- |
| Inadequate early molecular response | Verify adherence, treatment interruptions, and clinically relevant drug interactions; repeat and trend standardized molecular testing. [21] | Consider alternate TKI therapy or clinical trial after evaluating reversible causes. [21] |
| Loss of prior response | Assess hematologic and cytogenetic status and obtain BCR::ABL1 kinase-domain mutation testing when response is unsatisfactory. [3][21] | Mutation findings and clinical context help guide subsequent treatment selection. [3] |
| Persistent intolerance despite response | Define toxicity severity, comorbid contributors, and patient treatment priorities. [1][4] | Individualize dose strategy or TKI change; long-term tolerability is a core management objective. [1] |

## Use standardized molecular monitoring to detect inadequate response early

Molecular kinetics direct the next clinical action and are more informative than symptoms alone during TKI treatment.

Quantitative BCR::ABL1 measurement by PCR standardized to the International Scale is an essential component of CML management. Serial molecular testing provides a precise, minimally invasive measure of response and should be interpreted longitudinally in the context of baseline transcript type, treatment exposure, adherence, and assay performance. [21]

A BCR::ABL1 level of 10% or less on the International Scale is a cited early response milestone at 3 and 6 months. Historical NCCN guidance recommended continued same-dose TKI therapy with testing every 3 months for patients at or below this level, while levels above 10% triggered reassessment, including adherence and drug-interaction review, and consideration of another TKI or a clinical trial. Current decisions should be reconciled with the latest NCCN guidance. [21]

Failure and warning are distinct ELN response categories. Failure generally requires a therapy change after nonadherence is considered; warning permits either continuation or change after integrating molecular-response kinetics, comorbidities, tolerance, and patient characteristics. [3]
- Use the same validated laboratory methodology whenever feasible and confirm unexpected molecular changes before irreversible treatment decisions. The supplied sources emphasize harmonized molecular monitoring but do not provide an assay-variability threshold. [11][21]
- Obtain BCR::ABL1 kinase-domain mutation testing for unsatisfactory response, including inadequate initial response or loss of response. [3][21]
- Reports should use unambiguous HGVS nomenclature and may also state the commonly used abbreviated variant name, such as T315I. [3]

*Response findings and actions supported by available guideline summaries. [3][21]*

| Finding | Recommended evaluation | Potential next step |
| --- | --- | --- |
| BCR::ABL1 >10% at 3 or 6 months on International Scale | Evaluate adherence and drug interactions; reassess molecular response. [21] | Consider alternate TKI therapy or clinical trial in the appropriate clinical context. [21] |
| Loss of hematologic or cytogenetic response | Obtain BCR::ABL1 kinase-domain mutation analysis and evaluate treatment exposure. [21] | Change therapy when failure is established, accounting for mutation profile and tolerance. [3] |
| One-log BCR::ABL1 increase with loss of major molecular response | Perform mutation analysis and evaluate for loss of response. [21] | Use findings to guide treatment reassessment. [21] |
| ELN warning response | Review response kinetics, comorbidities, tolerance, and patient factors. [3] | Either continue or change therapy after individualized assessment. [3] |

## Treat suspected resistance as a diagnostic problem before switching therapy

Biologic resistance, inadequate exposure, and treatment intolerance require different interventions.

Selective pressure from TKI therapy can permit emergence of BCR::ABL1 kinase-domain mutations. Mutation testing is intended to support clinical decision-making when response is unsatisfactory, not as routine baseline testing in chronic-phase disease. [3]

When response is inadequate, distinguish pharmacologic or behavioral causes from resistant disease: verify medication access and adherence, review interacting drugs, establish whether the molecular rise is confirmed, reassess disease phase, and obtain mutation testing when indicated. A response categorized as failure usually mandates treatment change, whereas warning status is less deterministic. [3][21]

Accelerated- and blast-phase CML require urgent specialist-directed management. The supplied sources confirm that CML occurs in chronic, accelerated, and blast phases and that preventing progression is the central goal of chronic-phase treatment, but do not provide sufficiently detailed evidence for a phase-specific regimen or transplant algorithm. [18]
- Do not interpret a kinase-domain result in isolation; treatment choice must incorporate mutation status, prior TKI exposure, comorbidities, and tolerability. [3]
- T315I should be reported with standardized nomenclature; it is commonly represented as NM_005157.6:c.944C>T, p.Thr315Ile. [3]
- Consider clinical-trial referral when chronic-phase disease has inadequate response despite appropriate TKI exposure or when disease progresses. [21]

*Practical sequence for an inadequate molecular response. [3][21]*

| Step | Action | Reason |
| --- | --- | --- |
| 1 | Confirm serial quantitative BCR::ABL1 result and review test context. [21] | Avoid acting on an isolated value without clinical correlation. [21] |
| 2 | Assess adherence, dose interruptions, access barriers, and drug interactions. [3][21] | Correctable underexposure can mimic treatment failure. [3][21] |
| 3 | Reassess hematologic and cytogenetic status and evaluate for phase progression. [18][21] | Disease phase changes prognosis and management urgency. [18] |
| 4 | Order BCR::ABL1 kinase-domain mutation testing when response is unsatisfactory. [3][21] | Results support selection of subsequent therapy. [3] |

## Consider treatment-free remission only with structured molecular surveillance

Discontinuation is a monitored treatment strategy, not a declaration of cure.

Deep molecular responses achieved during TKI therapy have made treatment-free remission feasible for selected patients. Both NCCN and ELN-oriented sources emphasize that discontinuation requires careful monitoring rather than routine cessation after a favorable response. [1][18]

The available sources do not provide sufficient detail to specify a U.S. eligibility duration, exact deep-response threshold, post-discontinuation testing schedule, or molecular trigger for restarting therapy. In practice, use current guideline criteria and ensure reliable access to rapid, standardized BCR::ABL1 testing before discussing a discontinuation attempt. [1][18]
- Frame TKI discontinuation as an option for selected patients, not the primary goal for every patient. Long-term response, safety, and quality of life remain coequal priorities. [1]
- Do not attempt treatment-free remission without a plan for frequent molecular surveillance and prompt re-treatment if molecular relapse occurs. [18]

*Conditions that should be addressed before discussing TKI discontinuation. [1][18]*

| Domain | Clinical requirement |
| --- | --- |
| Disease response | Sustained deep molecular response is the basis for considering a discontinuation trial in selected patients. [1] |
| Monitoring infrastructure | Careful molecular monitoring must be available after stopping therapy. [18] |
| Shared decision-making | Balance interest in treatment-free remission against the possibility of renewed therapy and the need for intensive surveillance. [1][18] |

## Common questions

### What is the preferred test for monitoring response in CML?

Use serial quantitative BCR::ABL1 PCR reported on the International Scale when available. It provides a precise longitudinal measure of TKI response and supports milestone-based reassessment. [21]

### When should BCR::ABL1 kinase-domain mutation testing be ordered?

Order testing when response is unsatisfactory, including inadequate initial response, loss of hematologic or cytogenetic response, or a one-log transcript increase accompanied by loss of major molecular response. [3][21]

### Does a BCR::ABL1 level above 10% at 3 months prove TKI resistance?

No. A value above 10% is an adverse early response finding that should prompt evaluation of adherence, drug interactions, and response trajectory, with consideration of alternate therapy or clinical trial as appropriate. [21]

### Can patients with chronic-phase CML stop TKI therapy?

Selected patients with sufficiently deep molecular responses may attempt treatment discontinuation, but only with careful molecular monitoring. The supplied evidence does not define current U.S. eligibility criteria or surveillance intervals. [1][18]

## References
1. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia | Leukemia — www.nature.com — https://www.nature.com/articles/s41375-025-02664-w
2. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia | Leukemia — www.nature.com — https://www.nature.com/articles/s41375-020-0776-2
3. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia | Leukemia — www.nature.com — https://www.nature.com/articles/s41375-023-02048-y
4. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia | Leukemia — www.nature.com — https://www.nature.com/articles/leu2016104
5. Chronic myeloid leukemia: 2022 update on diagnosis, ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.26642
6. Early cytogenetic and molecular response during firstâ•'line ... — acsjournals.onlinelibrary.wiley.com — https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.26196
7. Chronic myeloid leukemia: 2018 update on diagnosis, ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.25011
8. Improving the Diagnosis and Follow‐Up of Chronic ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/jcla.70001
9. American Journal of Hematology | Blood Research Journal — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.21954
10. American Association of Neuropathologists, Inc. Abstracts of ... — academic.oup.com — https://academic.oup.com/jnen/article/72/6/540/2917641
11. Chronic Myeloid Leukemia in 2020 : HemaSphere — journals.lww.com — https://journals.lww.com/hemasphere/fulltext/2020/10000/chronic_myeloid_leukemia_in_2020.22.aspx
12. Management of chronic myeloid leukemia in 2025 - Kantarjian — acsjournals.onlinelibrary.wiley.com — https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35953
13. A new chapter in CML treatment: the promise of... : Annals of Medicine & Surgery — journals.lww.com — https://journals.lww.com/annals-of-medicine-and-surgery/fulltext/2025/03000/a_new_chapter_in_cml_treatment__the_promise_of.10.aspx?context=latestarticles
14. Management of chronic myeloid leukemia (CML) in ... — journals.lww.com — https://journals.lww.com/aob/_layouts/15/oaks.journals/downloadpdf.aspx?an=02026214-202403000-00005
15. Determinants of frontline tyrosine kinase inhibitor choice for ... — acsjournals.onlinelibrary.wiley.com — https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.34923
16. Olverembatinib in chronic myeloid leukemia—Review of ... — acsjournals.onlinelibrary.wiley.com — https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.35832
17. 103 Pregnancy Outcomes in Chronic Myeloid Leukemia (CML) — academic.oup.com — https://academic.oup.com/ajcp/article/149/suppl_1/S44/4801393
18. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology - PubMed — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/38394770
19. Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10084831
20. Current Practices in the Management of Chronic Myeloid ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC3645375
21. Chronic Myelogenous Leukemia, Version 1.2014 — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4234105
22. Guide to Interpreting Disease Responses in Chronic Myeloid ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4093342
23. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/30181422
24. Guidelines for the treatment of chronic myeloid leukemia ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/36064839

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.